吡格列酮与膀胱癌：一项基于台湾人群的研究。
Pioglitazone and bladder cancer: a population-based study of Taiwanese.
机构信息
Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
出版信息
Diabetes Care. 2012 Feb;35(2):278-80. doi: 10.2337/dc11-1449. Epub 2011 Dec 30.
Abstract
OBJECTIVE
The association between pioglitazone and bladder cancer has not been investigated in Asians. We aimed to investigate this association.
RESEARCH DESIGN AND METHODS
A total of 1,000,000 individuals were randomly sampled from the National Health Insurance database, and incident cases of bladder cancer during the period from 1 January 2006 to 31 December 2009 were analyzed among 54,928 patients with type 2 diabetes and without previous bladder cancer.
RESULTS
Among 165 incident case subjects, 10 (0.39%) were ever users and 155 (0.30%) were never users of pioglitazone (adjusted hazard ratio in full model 1.305 [95% CI 0.661-2.576]). All bladder cancer in ever users occurred within a duration of therapy <24 months, suggesting an early effect of pioglitazone on bladder cancer or late use of pioglitazone in high-risk patients.
CONCLUSIONS
The association between pioglitazone and bladder cancer was not significant. However, confirmation of this finding is required because of the possible lack of statistical power owing to the small number of events.
摘要
目的
吡格列酮与膀胱癌之间的关联尚未在亚洲人群中进行过研究。本研究旨在对此关联进行探讨。
研究设计与方法
从国家健康保险数据库中随机抽取了 100 万人作为样本，对 2006 年 1 月 1 日至 2009 年 12 月 31 日期间患有 2 型糖尿病且无膀胱癌既往史的 54928 例患者进行了分析，观察其间膀胱癌的发病情况。
结果
在 165 例新发膀胱癌病例中，10 例（0.39%）为吡格列酮曾用者，155 例（0.30%）为从未使用者（全模型校正后 HR 为 1.305[95%CI 0.661-2.576]）。所有曾用者的膀胱癌均发生在治疗时间<24 个月内，提示吡格列酮对膀胱癌具有早期作用，或在高危患者中存在延迟使用吡格列酮的情况。
结论
吡格列酮与膀胱癌之间的关联并不显著。但是，由于事件数量较少，可能存在统计学效能不足的问题，因此需要进一步确认这一发现。
相似文献
1
Pioglitazone and bladder cancer: a population-based study of Taiwanese.吡格列酮与膀胱癌：一项基于台湾人群的研究。
Diabetes Care. 2012 Feb;35(2):278-80. doi: 10.2337/dc11-1449. Epub 2011 Dec 30.
2
The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.吡格列酮与 2 型糖尿病台湾患者尿路疾病的相关性：膀胱癌和慢性肾脏病。
PLoS One. 2014 Jan 10;9(1):e85479. doi: 10.1371/journal.pone.0085479. eCollection 2014.
3
Pioglitazone use and the risk of bladder cancer.吡格列酮的使用与膀胱癌风险。
Kaohsiung J Med Sci. 2014 Feb;30(2):94-7. doi: 10.1016/j.kjms.2013.09.011. Epub 2013 Oct 29.
4
Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.吡格列酮的使用与2型糖尿病患者膀胱癌风险：利用四个欧洲国家数据集的回顾性队列研究
BMJ. 2016 Aug 16;354:i3903. doi: 10.1136/bmj.i3903.
5
Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.吡格列酮与法国糖尿病患者膀胱癌风险：一项基于人群的队列研究。
Diabetologia. 2012 Jul;55(7):1953-62. doi: 10.1007/s00125-012-2538-9. Epub 2012 Mar 31.
6
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.吡格列酮治疗的糖尿病患者膀胱癌风险：一项纵向队列研究的中期报告。
Diabetes Care. 2011 Apr;34(4):916-22. doi: 10.2337/dc10-1068.
7
Bladder cancer with pioglitazone: A case-control study.吡格列酮相关膀胱癌：一项病例对照研究。
Diabetes Metab Syndr. 2022 Nov;16(11):102637. doi: 10.1016/j.dsx.2022.102637. Epub 2022 Oct 8.
8
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.吡格列酮的使用与糖尿病患者膀胱癌和其他常见癌症的风险。
JAMA. 2015 Jul 21;314(3):265-77. doi: 10.1001/jama.2015.7996.
9
Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.罗格列酮的使用与2型糖尿病患者膀胱癌风险
Medicine (Baltimore). 2016 Feb;95(6):e2786. doi: 10.1097/MD.0000000000002786.
10
The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.吡格列酮的使用与 2 型糖尿病患者膀胱癌风险：巢式病例对照研究。
BMJ. 2012 May 30;344:e3645. doi: 10.1136/bmj.e3645.
引用本文的文献
1
Sodium-glucose cotransporter 2 inhibitors and renal cancer in the US FDA adverse event reporting system.钠-葡萄糖共转运蛋白 2 抑制剂与美国食品药品监督管理局不良事件报告系统中的肾癌。
Eur J Clin Pharmacol. 2024 Dec;80(12):1959-1966. doi: 10.1007/s00228-024-03759-6. Epub 2024 Sep 17.
2
Cancer biology in diabetes update: Focusing on antidiabetic drugs.糖尿病相关癌症生物学研究进展：聚焦于抗糖尿病药物。
J Diabetes Investig. 2024 May;15(5):525-540. doi: 10.1111/jdi.14152. Epub 2024 Mar 8.
3
Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan.在台湾，噻唑烷二酮类药物的使用与2型糖尿病患者多发性骨髓瘤风险略低以及死亡风险显著降低相关。
Cancers (Basel). 2023 Aug 26;15(17):4276. doi: 10.3390/cancers15174276.
4
SGLT-2 Inhibitors in Cancer Treatment-Mechanisms of Action and Emerging New Perspectives.SGLT-2抑制剂在癌症治疗中的作用机制及新出现的观点
Cancers (Basel). 2022 Nov 25;14(23):5811. doi: 10.3390/cancers14235811.
5
Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.吡格列酮与 2 型糖尿病女性患者乳腺癌风险：一项回顾性队列分析。
BMC Cancer. 2022 May 18;22(1):559. doi: 10.1186/s12885-022-09660-8.
6
Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study.吡格列酮与 2 型糖尿病患者慢性阻塞性肺疾病风险：一项回顾性队列研究。
Int J Chron Obstruct Pulmon Dis. 2022 Feb 9;17:285-295. doi: 10.2147/COPD.S345796. eCollection 2022.
7
Insulin Resistance and Cancer: In Search for a Causal Link.胰岛素抵抗与癌症：探寻因果关联。
Int J Mol Sci. 2021 Oct 15;22(20):11137. doi: 10.3390/ijms222011137.
8
Type 2 Diabetic Sepsis Patients Have a Lower Mortality Rate in Pioglitazone Use: A Nationwide 15-Year Propensity Score Matching Observational Study in Taiwan.使用吡格列酮的2型糖尿病脓毒症患者死亡率较低：台湾一项为期15年的全国性倾向评分匹配观察性研究
Emerg Med Int. 2021 Jul 23;2021:4916777. doi: 10.1155/2021/4916777. eCollection 2021.
9
A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone.一项评估接受吡格列酮治疗的2型糖尿病患者患膀胱癌风险的回顾性研究。
Perspect Clin Res. 2021 Jan-Mar;12(1):9-13. doi: 10.4103/picr.PICR_192_18. Epub 2019 Sep 5.
10
Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes.研究设计选择评估糖尿病药物比较安全性：评估吡格列酮在老年美国 2 型糖尿病患者中的使用与膀胱癌风险。
Diabetes Obes Metab. 2019 Sep;21(9):2096-2106. doi: 10.1111/dom.13774. Epub 2019 Jun 17.
本文引用的文献
1
Comment: analyses using time-dependent pioglitazone usage in Cox models may lead to wrong conclusions about its association with cancer.评论：在Cox模型中使用随时间变化的吡格列酮使用情况进行分析，可能会得出关于其与癌症关联的错误结论。
Diabetes Care. 2011 Aug;34(8):e136; author reply 137. doi: 10.2337/dc11-0627.
2
Diabetes and non-Hodgkin's lymphoma: analyses of prevalence and annual incidence in 2005 using the National Health Insurance database in Taiwan.糖尿病与非霍奇金淋巴瘤：2005 年基于台湾全民健康保险数据库的流行率与年发病率分析。
Ann Oncol. 2012 Jan;23(1):153-158. doi: 10.1093/annonc/mdr334. Epub 2011 Jul 15.
3
Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan.糖尿病与膀胱癌风险：一项基于台湾全民健康保险数据库的研究。
Diabetologia. 2011 Aug;54(8):2009-15. doi: 10.1007/s00125-011-2171-z. Epub 2011 May 5.
4
[Regression modeling strategies].[回归建模策略]
Rev Esp Cardiol. 2011 Jun;64(6):501-7. doi: 10.1016/j.recesp.2011.01.019. Epub 2011 Apr 29.
5
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.通过药物不良反应报告评估吡格列酮的使用与膀胱癌的关联性。
Diabetes Care. 2011 Jun;34(6):1369-71. doi: 10.2337/dc10-2412. Epub 2011 Apr 22.
6
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.吡格列酮治疗的糖尿病患者膀胱癌风险：一项纵向队列研究的中期报告。
Diabetes Care. 2011 Apr;34(4):916-22. doi: 10.2337/dc10-1068.
7
Diabetes and risk of prostate cancer: a study using the National Health Insurance.糖尿病与前列腺癌风险：基于国民健康保险的研究。
Diabetes Care. 2011 Mar;34(3):616-21. doi: 10.2337/dc10-1640. Epub 2011 Jan 27.
8
Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.二甲双胍与糖尿病患者的癌症风险：系统评价和荟萃分析。
Cancer Prev Res (Phila). 2010 Nov;3(11):1451-61. doi: 10.1158/1940-6207.CAPR-10-0157. Epub 2010 Oct 12.
9
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.降糖治疗对 2 型糖尿病患者癌症风险的影响。
Diabetologia. 2009 Sep;52(9):1766-77. doi: 10.1007/s00125-009-1440-6. Epub 2009 Jul 2.
10
Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive.吡格列酮在2型糖尿病高危患者中的安全性和耐受性：PROactive研究数据概述
Drug Saf. 2009;32(3):187-202. doi: 10.2165/00002018-200932030-00002.
Zotero 插件